1. CTNI-24. A PHASE 1/2 STUDY OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING. (12th November 2021) Authors: Chi, Susan; Hsieh, Antony; Foley, Megan; Shi, Hongliang; Swamy, Preethi; Rodstrom, Jill; Rudoltz, Marc Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS. (1st June 2021) Authors: Chi, Susan; Hsieh, Antony; Foley, Megan; Shi, Hongliang; Swamy, Preethi; Rodstrom, Jill; Rudoltz, Marc Journal: Neuro-oncology Issue: Volume 23(2021)Supplement 1 Page Start: i47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EPCT-09. ROVER: A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling. (3rd June 2022) Authors: Chi, Susan; Hsieh, Antony; Foley, Megan; Shi, Hongliang; Swamy, Preethi; Rodstrom, Jill; Rudoltz, Marc Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 1 Page Start: i37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗